

#2237 Store at -20°C

Phospho-EGF Receptor (Tyr1045) Antibody

100 µl
 (10 western blots)



Orders ■ 877-616-CELL (2355)
 orders@cellsignal.com
Support ■ 877-678-TECH (8324)
 info@cellsignal.com
Web ■ www.cellsignal.com

rev. 06/28/10


This product is intended for research purposes only. This product is not intended to be used for therapeutic or diagnostic purposes in humans or animals.

Applications	Species Cross-Reactivity*	Molecular Wt.	Source
W, IHC-P, IF-IC Endogenous	H, R	175 kDa	Rabbit**


Background: The epidermal growth factor (EGF) receptor is a 170 kDa transmembrane tyrosine kinase that belongs to the HER/ErbB protein family. Ligand binding results in receptor dimerization, autophosphorylation, activation of downstream signaling, internalization and lysosomal degradation (1,2). Phosphorylation of EGF receptor (EGFR) at Tyr845 in the kinase domain is implicated in stabilizing the activation loop, maintaining the active state enzyme and providing a binding surface for substrate proteins (3,4). c-Src is involved in phosphorylation of EGFR at Tyr845 (5). The SH2 domain of PLCγ binds at phospho-Tyr992, resulting in activation of PLCγ-mediated downstream signaling (6). Phosphorylation of EGFR at Tyr1045 creates a major docking site for c-Cbl, an adaptor protein that leads to receptor ubiquitination and degradation following EGFR activation (7,8). The GRB2 adaptor protein binds activated EGFR at phospho-Tyr1068 (9). A pair of phosphorylated EGFR residues (Tyr1148 and Tyr1173) provides a docking site for the Shc scaffold protein, with both sites involved in MAP kinase signaling activation (2). Phosphorylation of EGFR at specific serine and threonine residues attenuates EGFR kinase activity. EGFR carboxy-terminal residues Ser1046 and Ser1047 are phosphorylated by CaM kinase II; mutation of either of these serines results in upregulated EGFR tyrosine autophosphorylation (10).

Specificity/Sensitivity: Phospho-EGF Receptor (Tyr1045) Antibody detects EGF receptor only when phosphorylated at tyrosine1045. The antibody may cross-react with other activated EGF receptor family members (e.g. ErbB2).

Source/Purification: Polyclonal antibodies are produced by immunizing animals with a synthetic phosphopeptide corresponding to residues surrounding Tyr1045 of human EGF receptor. Antibodies are purified by protein A and peptide affinity chromatography.



Western blot analysis of extracts from A431 cells, untreated or EGF-stimulated (100 ng/ml), using Phospho-EGF Receptor (Tyr1045) Antibody (upper) or EGF Receptor (C74B9) Rabbit mAb #2646 (lower).



Immunohistochemical analysis of paraffin-embedded human breast carcinoma, showing membrane and cytoplasmic localization, using Phospho-EGF Receptor (Tyr1045) Antibody.

Entrez-Gene ID # 1956
 Swiss-Prot Acc. # P00533

Storage: Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. Store at -20°C. Do not aliquot the antibody.

*Species cross-reactivity is determined by western blot.


**Anti-rabbit secondary antibodies must be used to detect this antibody.

Recommended Antibody Dilutions:

Western blotting	1:1000
Immunohistochemistry (Paraffin)	1:200
Unmasking buffer:	EDTA
Antibody diluent:	TBST-5%NGS
Immunofluorescence (IF-IC)	1:50


For application specific protocols please see the web page for this product at www.cellsignal.com.

Please visit www.cellsignal.com for a complete listing of recommended companion products.



IMPORTANT: For western blots, incubate membrane with diluted antibody in 5% w/v BSA, 1X TBS, 0.1% Tween-20 at 4°C with gentle shaking, overnight.

DRAQ5® is a registered trademark of Biostatus Limited.



Confocal immunofluorescent analysis of A431 cells serum-starved (left) or EGF-treated (right) and labeled with Phospho-EGF Receptor (Tyr1045) Antibody (green). Blue pseudocolor = DRAQ5® #4084 (fluorescent DNA dye).

Background References:

- (1) Hackel, P.O. et al. (1999) *Curr. Opin. Cell Biol.* 11, 184–189.
- (2) Zwick, E. et al. (1999) *Trends Pharmacol. Sci.* 20, 408–412.
- (3) Cooper, J.A. and Howell, B. (1993) *Cell* 73, 1051–1054.
- (4) Hubbard, S.R. et al. (1994) *Nature* 372, 746–754.
- (5) Biscardi, J.S. et al. (1999) *J. Biol. Chem.* 274, 8335–8343.
- (6) Emlet, D.R. et al. (1997) *J. Biol. Chem.* 272, 4079–4086.
- (7) Levkowitz, G. et al. (1999) *Mol. Cell* 4, 1029–1040.
- (8) Ettenberg, S.A. et al. (1999) *Oncogene* 18, 1855–1866.
- (9) Rojas, M. et al. (1996) *J. Biol. Chem.* 271, 27456–27461.
- (10) Feinmesser, R.L. et al. (1999) *J. Biol. Chem.* 274, 16168–16173.